Guardant Health
394 hedge funds and large institutions have $7.65B invested in Guardant Health in 2025 Q3 according to their latest regulatory filings, with 71 funds opening new positions, 134 increasing their positions, 132 reducing their positions, and 39 closing their positions.
82% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 39
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
18% more capital invested
Capital invested by funds: $6.47B → $7.65B (+$1.19B)
8% more funds holding
Funds holding: 364 → 394 (+30)
2% more repeat investments, than reductions
Existing positions increased: 134 | Existing positions reduced: 132
10% less call options, than puts
Call options by funds: $156M | Put options by funds: $173M
2.09% less ownership
Funds ownership: 100.34% → 98.24% (-2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$134M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$99.6M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$74.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$72.1M |
| 5 |
Jennison Associates
New York
|
+$41.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$143M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$110M |
| 3 |
Millennium Management
New York
|
-$100M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
-$69.4M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$69.4M |
GH Hedge Fund Activity: Q3 2025 in Review
394 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Guardant Health (GH) for Q3 2025, worth a combined $7.65B — up 18% from $6.47B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new GH positions and 39 closed out — a net gain of 32 holders — while 134 added to existing stakes and 132 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $134M. The largest seller was Citadel Advisors, cutting an estimated $143M.
- 394 institutional investors held Guardant Health (GH) as of Q3 2025, up from 364 in Q2 2025.
- Funds reported $7.65B of Guardant Health stock for Q3 2025, up 18% quarter-over-quarter.
- 71 funds opened new Guardant Health positions in Q3 2025 and 39 closed out, a net change of +32 holders.
- The largest Guardant Health buyer in Q3 2025 was T. Rowe Price Associates, an estimated $134M added.
- The largest Guardant Health seller in Q3 2025 was Citadel Advisors, an estimated $143M sold.
Based on aggregated 13F filings for Q3 2025.